Figure 1. Mean UAS7 and CUQoLTS at each visit during the study.
Mean Difference (95%CI) from the post-placebo visit (visit 2) to the
respective visits are shown.
Table-1. Differences between Benralizumab responders (either
complete i.e., UAS7=0 at visit 5, or partial i.e., UAS7≤6 at visit 5,
n=7) versus non-responders (n=2) using per protocol analysis (i.e.,
subjects completing the study, n=9).